ArticleClinical pharmacology and therapeutics2025
Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments.
Hiroe Kitagaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it